Opioid Treatment Providers Act

Bill 117 HR 4051, also known as the Opioid Treatment Providers Act, is a piece of legislation introduced in the US Congress aimed at addressing the opioid crisis in the country. The bill focuses on expanding access to treatment for individuals struggling with opioid addiction by increasing the number of providers who are able to prescribe medication-assisted treatment (MAT) for opioid use disorder.

Specifically, the Opioid Treatment Providers Act seeks to remove the current requirement that providers must obtain a waiver from the Drug Enforcement Administration (DEA) in order to prescribe buprenorphine, a medication commonly used in MAT. By eliminating this waiver requirement, the bill aims to make it easier for healthcare providers, including nurse practitioners and physician assistants, to offer MAT to patients in need.

Additionally, the bill includes provisions to increase training and education for healthcare providers on the use of MAT and best practices for treating opioid addiction. It also calls for the establishment of a national registry of providers who are authorized to prescribe buprenorphine without a waiver, in order to ensure transparency and accountability in the prescribing process. Overall, the Opioid Treatment Providers Act is designed to improve access to evidence-based treatment for individuals struggling with opioid addiction, with the goal of reducing overdose deaths and improving outcomes for those affected by this public health crisis.